Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results PR_BPTH_20120403YrEndFinancialResults
Bio-Path Holdings Engages PondelWilkinson for Retailer Investor Relations Program PR_BPTH_20120329PondelWilkinson
Bio-Path Holdings Successfully Completes Second Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia PR20120207
Bio-Path Holdings’ Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-101-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose PR_Data_from_Phase_I_Clinical_Trial_Presented
Bio-Path Holdings to Present at the 10th Annual BIO Investors Forum Conference in San Francisco on Wednesday, October 26, 2011. Link to Conference at 3:00pm Pacific Time PR_Bio_Investor_Forum
Initial Data from Bio-Path Holdings’ Phase I Clinical Trial Accepted for Presentation at American Society ofHematology Annual Meeting PR_BPTH_2011_10_04
Bio-Path Holdings to Present at the Rodman & RenshawAnnual Global Investment Conference BPTH Rodman Conf Alert 2011 09 06
